I-Mab to Present at Jefferies Global Healthcare Conference
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents, has announced its participation in the Jefferies Global Healthcare Conference scheduled for June 3-5, 2025. The company's management will engage in a fireside chat and one-on-one meetings on June 5 at 3:45 PM ET.
Additionally, I-Mab revealed that new data regarding their lead program, givastomig, has been accepted for a Mini Oral presentation at the ESMO GI Cancers Congress 2025, taking place on July 2, 2025, in Barcelona, Spain.
I-Mab (NASDAQ: IMAB), un'azienda biotecnologica globale con sede negli Stati Uniti specializzata in agenti immuno-oncologici di precisione, ha annunciato la sua partecipazione alla Jefferies Global Healthcare Conference prevista dal 3 al 5 giugno 2025. Il management della società parteciperà a una conversazione informale e a incontri individuali il 5 giugno alle 15:45 ET.
Inoltre, I-Mab ha comunicato che nuovi dati riguardanti il loro programma principale, givastomig, sono stati accettati per una presentazione Mini Oral al ESMO GI Cancers Congress 2025, che si terrà il 2 luglio 2025 a Barcellona, Spagna.
I-Mab (NASDAQ: IMAB), una compañía biotecnológica global con sede en EE. UU. especializada en agentes inmunooncológicos de precisión, ha anunciado su participación en la Jefferies Global Healthcare Conference programada del 3 al 5 de junio de 2025. La dirección de la empresa participará en una charla informal y en reuniones individuales el 5 de junio a las 3:45 PM ET.
Además, I-Mab reveló que nuevos datos sobre su programa principal, givastomig, han sido aceptados para una presentación Mini Oral en el ESMO GI Cancers Congress 2025, que se celebrará el 2 de julio de 2025 en Barcelona, España.
I-Mab (NASDAQ: IMAB)는 정밀 면역항암제를 전문으로 하는 미국 기반의 글로벌 바이오테크 기업으로, 2025년 6월 3일부터 5일까지 예정된 Jefferies Global Healthcare Conference에 참가한다고 발표했습니다. 회사 경영진은 6월 5일 오후 3시 45분(동부시간)에 파이어사이드 채팅과 일대일 미팅에 참여할 예정입니다.
또한 I-Mab은 주력 프로그램인 givastomig 관련 새로운 데이터가 2025년 7월 2일 스페인 바르셀로나에서 열리는 ESMO GI Cancers Congress 2025에서 미니 오럴 발표로 채택되었다고 밝혔습니다.
I-Mab (NASDAQ : IMAB), une société biotechnologique mondiale basée aux États-Unis spécialisée dans les agents d'immuno-oncologie de précision, a annoncé sa participation à la Jefferies Global Healthcare Conference prévue du 3 au 5 juin 2025. La direction de l'entreprise participera à une discussion informelle et à des réunions individuelles le 5 juin à 15h45, heure de l'Est.
De plus, I-Mab a révélé que de nouvelles données concernant leur programme principal, givastomig, ont été acceptées pour une présentation Mini Oral lors du ESMO GI Cancers Congress 2025, qui se tiendra le 2 juillet 2025 à Barcelone, en Espagne.
I-Mab (NASDAQ: IMAB), ein globales Biotech-Unternehmen mit Sitz in den USA, das sich auf präzise Immunonkologie-Agentien spezialisiert hat, hat seine Teilnahme an der Jefferies Global Healthcare Conference angekündigt, die vom 3. bis 5. Juni 2025 stattfindet. Das Management des Unternehmens wird am 5. Juni um 15:45 Uhr ET an einem Fireside-Chat und Einzelgesprächen teilnehmen.
Darüber hinaus gab I-Mab bekannt, dass neue Daten zu ihrem führenden Programm givastomig für eine Mini-Oral-Präsentation auf dem ESMO GI Cancers Congress 2025 angenommen wurden, der am 2. Juli 2025 in Barcelona, Spanien, stattfindet.
- None.
- None.
ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the Jefferies Global Healthcare Conference, being held June 3-5, 2025. During the event, I-Mab’s management will discuss clinical progress on its lead program, givastomig.
I-Mab also recently announced that new data on givastomig has been accepted for a Mini Oral presentation at the European Society of Medical Oncology (“ESMO”) Gastrointestinal (“GI”) Cancers Congress 2025, scheduled for July 2, 2025, in Barcelona, Spain.
Conference details are as follows:
Jefferies Global Healthcare Conference
Format: Fireside Chat and one-on-one meetings
Date: Thursday, June 5, 2025
Time: 3:45 PM ET
Webcast Link: Register here
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
I-Mab Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
IR@imabbio.com
FAQ
What will I-Mab (IMAB) present at the Jefferies Global Healthcare Conference 2025?
When and where will I-Mab present new givastomig data at ESMO GI 2025?
What is I-Mab's (IMAB) main focus as a company?
What is givastomig and why is it important for I-Mab?
